Phil Chamberlain
Co-Founder, President & Chief Executive Officer Neomorph
Seminars
Wednesday 28th October 2026
Panel Discussion: Shaping Investment in Induced Proximity: Insights to Accelerate Development & Secure Funding
9:30 am
- Exploring the data, targets, and indications investors are prioritizing to support next-generation induced proximity therapeutics
- Discussing funding strategies for early-stage companies, including milestones needed to secure investment and attract pharmaceutical partnerships
- Evaluating how scientific innovation and emerging modalities influence investor confidence and the types of assets and platforms likely to attract investor interest
Tuesday 27th October 2026
Development of NEO-811, a Molecular Glue Degrader of ARNT (HIF-1β) with Potent Single Agent Activity in ccRCC
2:40 pm
- Targeting an “undruggable” node
- Discovery and mechanism
- Preclinical efficacy and clinical progress
